Could global standardization of A1C help it become the preferred diabetes screening method? by Bennett, Catherine M et al.
Deakin Research Online 
Deakin University’s institutional research repository 
DDeakin Research Online  
Research Online  
This is the published version (version of record) of: 
 
Bennett, Catherine M, Jenkins, Alicia J., Guo, Mei and Dharmage, Shymali C. 2007-06, 
Could global standardization of A1C help it become the preferred diabetes screening 
method?, Review of endocrinology, no. June, pp. 59-61. 
 
Available from Deakin Research Online: 
http://hdl.handle.net/10536/DRO/DU:30021870 
 
 
Reproduced with the kind permission of the copyright owner. 
 
Copyright : 2007, Bryn Mawr Communications 
JUNE 2007 I REVIEW OF ENDOCRINOLOGY I 59
S
creening for type 2 diabetes is advantageous as
it permits early diagnosis, enabling early dia-
betes treatment and therefore reducing the risk
of complications. Although diabetes is rapidly
emerging as a public health issue in both developed
and developing countries, consensus has not yet been
reached on the most useful and accurate screening
test for the detection of type 2 diabetes. 
The tests most widely used in clinical practice today
are the fasting plasma glucose screening test (FPG) for
type 2 diabetes and the confirmatory oral glucose tol-
erance test (OGTT). Both involve measurement of
venous (not capillary) blood glucose, and both require
patients to fast overnight for at least 8 hours, be on a
normal diet, and be free of intercurrent illness. FPG-
based diagnoses also require at least two elevated FPG
levels, limiting the practicality of these tests in rural
and remote settings where laboratory access is limited.
OGGTT IS COSTLY, TIME CONSUMING 
The “gold standard” OGTT, on the other hand, is rel-
atively costly, time consuming and labor intensive.
Reproducibility for OGTT is also low with intra-indi-
vidual coefficients of up to 16.7%.1 These rates are
higher than those reported for FPG (up to 11.4%)1 and
may indicate increased diagnosis error rates,2 high-
lighting the fact that there is no true gold standard
diagnostic test for evaluating the sensitivity and speci-
ficity of alternative diabetes screening tests. 
The glycated hemoglobin test (A1C) is one alterna-
tive screening tool that deserves greater attention.
Although it has much greater sample stability, it is cur-
rently usually only used for monitoring purposes after
a diabetes diagnosis has been made. A1C has several
additional practical advantages over FPG or OGTT;
blood sample collection can be performed more
quickly, capillary blood samples are suitable, and sam-
ple stability is better than for blood glucose. 
A1C ADVANTAGE S
A1C has another important advantage in that levels
reflect the 2- to 3-month average of blood glucose con-
centrations, rather than the snapshot view provided by
blood glucose tests. A1C has also been demonstrated to
have less intraindividual variation (intraindividual coef-
ficient of variation of 4.2%, and even lower in longer-
term follow-up1), and to better predict both micro- 
and macrovascular diabetes complication risks.3
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The accuracy of A1C analysis may be influenced by
the presence of hemoglobinopathy or renal failure, as
well as laboratory error and/or the use of some med-
ications such as high-dose aspirin and opiates.4 These
potential confounders, however, are relatively easily
and reliably assessed in patients. A1C is also currently
a more expensive test option, and it is not readily
available to developing countries. Overall, A1C has a
number of practical advantages over OGTT; sample
collection and measurement is quicker and can be
taken regardless of prandial status, A1C can be ana-
lyzed with a small blood sample using a portable
device,5 and blood obtained from a finger stick can be
sent to a central laboratory for analysis, allowing
screening in remote areas.6,7
DR AWBACK:  
INCONSISTENCIE S IN REPORTING
A current drawback with regard to A1C testing is
that there is considerable inconsistency in the report-
ing of A1C results, making it difficult to compare
results across studies and populations. Progress is now
being made toward worldwide agreement on standard
A1C testing and result reporting.8 If this is successful, it
might facilitate an increase in the use of A1C as a dia-
betes screening test that, if substantial enough, could
drive the cost of testing down to a level comparable
with blood glucose tests. It is therefore timely to assess
the performance of A1C as a screening tool for dia-
betes compared with the blood glucose tests.
In a recent systematic review on the performance of
A1C as a diabetes screening tool,9 we analyzed the
benefits and limitations of the currently available A1C
assay. The review examined nine primary cross-sec-
tional studies of the accuracy of the A1C test for the
detection of type 2 diabetes using the OGTT as the
reference standard and FPG as the comparison.10-18
Some studies were community based,10-13 and others
hospital based.14-18 A barrier to evaluating the relative
value of A1C compared with other diabetes diagnostic
tests is the current inconsistency in reporting of A1C
results. Included studies either reported Diabetes
Control and Complications Trial (DCCT)-aligned A1C
results, or the published results were converted to the
equivalent DCCT-aligned values using conversion
regression models.19,20
Multiple A1C cutoff points were analyzed. In the
community-based studies, for the majority of cutoff
comparisons, A1C was found to have slightly lower
sensitivity for detecting diabetes than the FPG for
detecting diabetes, but slightly higher specificity. This
was seen for all comparisons in community-based
samples except for the A1C cutoff of 6.6% in which
specificity was comparable, but sensitivity was higher
for A1C (98% sensitivity for A1C in men compared
with 91% for FPG at 7 mmol/L11). The pattern was dif-
ferent in the hospital setting, with specificities general-
ly high across all tests and cut-off points compared. 
Across community and hospital settings, the sensi-
tivity for A1C at a DCCT-comparable cutoff point of
≥6.1% ranged from 78% to 81%, and the specificity
ranged from 79% to 84%. For FPG at a cut-off point of
≥6.1 mmol/L, the sensitivity ranged from 48% to 64%
and specificity from 94% to 98%. Not surprisingly,
both A1C and FPG have low sensitivity (around 50%)
for the detection of impaired glucose tolerance, which
is associated with an increased risk of type 2 diabetes2
and perhaps of atherosclerosis.21-24
A1C ,  FPG EQUALLY EFFECTIVE
The review confirmed that A1C and FPG are equally
effective screening tools for the detection of type 2
diabetes across a range of populations including
Australia, Asia, Europe, and the United States. The
A1C cutoff point of >6.1% was the recommended
optimum cut-off point for A1C in most of the
reviewed studies. There is also an argument, however,
for population-specific cutoff points, as reported opti-
mum cutoff points varied according to ethnic group,
age, and gender, as well as with the population preva-
lence of diabetes. 
If global reporting standards for the units reported
are successfully introduced in the near future,8 it may
encourage the more widespread application of A1C as
a diabetes screening test. If so, and given the reduced
sample collection time relative to an OGTT test, it is
likely this will drive down the cost of testing. A1C may
then become more widely available as a screening tool,
particularly in resource-poor populations who
arguably need it most—where diabetes is an emerging
public health issue but laboratory facilities are limited. 
With increased use across populations, it will be also
be important in the future to assess the potential for
improving sensitivity and specificity through the iden-
tification and application of population-specific cut-
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The review confirmed that A1C and
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of populations.
off points. In addition, the wider use of diagnostic
guidelines, such as the Australian guidelines,25 to iden-
tify patients at high risk for diabetes based on age,
positive family history, weight, comorbidities such as
vascular disease or polycystic ovary syndrome, and
prior gestational diabetes, will also result in more tar-
geted testing of high-risk groups, making diabetes
screening incorporating A1C (see sidebar) even more
efficient. ■
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A1c is also known as hemoglobin A1c, HbA1c, 
glycohemoglobin, glycated hemoglobin, 
and glycosylated hemoglobin
How is it used? The A1C test is used primarily to monitor
the glucose control of patients with diabetes over time. The
goal of those with diabetes is to keep their blood glucose
levels as close to normal as possible. This helps to minimize
the complications caused by chronically elevated glucose
levels, such as progressive damage to body organs like the
kidneys, eyes, cardiovascular system, and nerves. 
The A1C test gives a picture of the average amount of glu-
cose in the blood over the last few months. It can help
patients and physicians know if the measures they are tak-
ing to control diabetes are successful or need to be adjust-
ed. The A1C test is frequently ordered for newly diagnosed
diabetic patients to help determine how elevated their
uncontrolled blood glucose levels have been. It may be
ordered several times while control is being achieved and
then several times a year to verify that good control is being
maintained.
What does the test result mean? A 1% change in an A1C
result reflects a change of about 30 mg/dL (1.67 mmol/L) in
average blood glucose. For instance, an A1C of 6% corre-
sponds to an average glucose of 135 mg/dL (7.5 mmol/L),
while an A1C of 9% corresponds to an average glucose of
240 mg/dL (13.5 mmol/L). The closer a patient with dia-
betes can keep their A1C to 6%, the better their diabetes is
in control. As the A1C increases, so does the risk of compli-
cations.
Bear in mind that the correlation between mean plasma
glucose (MPG) levels and A1C levels is an estimation only,
dependent on methodology used for the calculation as well
as other factors, such as the red blood cells’ lifespan. The
exact MPG value reported on a laboratory report may not
coincide exactly with the formula given.
Source: www.labtestsonline.org
A1C: WHAT IS IT?
